Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30150290 | 1.00 | TLR2 (0.53) | TLR2ECE1PTPN1MDM2ITGB3 | |
| SCHEMBL20758974 | 0.99 | TLR2 (0.55) | TLR2ECE1PTPN1MDM2 | |
| SCHEMBL20759079 | 0.99 | TLR2 (0.55) | TLR2ECE1PTPN1MDM2 | |
| SCHEMBL20758846 | 0.99 | TLR2 (0.55) | TLR2ECE1PTPN1MDM2 | |
| SCHEMBL31566096 | 0.99 | TLR2 (0.55) | TLR2ECE1PTPN1MDM2 | |
| SCHEMBL30598967 | 0.96 | TLR2 (0.55) | TLR2ECE1PTPN1ITGB3ITGA2B | |
| SCHEMBL30099539 | 0.95 | PTPN1 (0.57) | TLR2ECE1PTPN1 | |
| SCHEMBL31138058 | 0.94 | PTPN1 (0.57) | TLR2PTPN1MDM2 | |
| SCHEMBL31212512 | 0.93 | TLR2 (0.59) | TLR2PTPN1MDM2 | |
| SCHEMBL31389333 | 0.92 | TLR2 (0.51) | TLR2ECE1PTPN1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | TLR2 2058/4885ECE1 2970/4885PTPN1 1798/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | TLR2 2058/4885ECE1 2970/4885PTPN1 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.